Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In patients with a sore throat that didn’t require immediate antibiotics, a single capsule of the corticosteroid dexamethasone didn’t increase the likelihood of complete symptom resolution after 24 hours, and although more patients taking the steroid reported feeling completely better after 48 hours, a role for steroids to treat sore throats in primary care is uncertain, according to a study published by JAMA

Acute sore throat is one of the most common symptoms among patients presenting to primary care. Adults in the United States made an estimated 92 million visits to doctors for sore throats between 1997 and 2010, an average of 6.6 million visits annually. Antibiotics are prescribed at 60 percent of UK primary care sore throat consultations, despite national guidelines advising against prescriptions. There is a need to find alternative strategies that reduce symptoms and antibiotic consumption.

Dr Gail Hayward of the University of Oxford, and colleagues randomly assigned adults with sore throat not requiring immediate antibiotics to a single oral dose of 10 mg of dexamethasone or placebo. The trial was conducted in 42 family practices in South and West England.

Dr Hayward is an Academic Clinical Lecturer in the Nuffield Department of Primary Care Health Sciences and a part-time Oxfordshire GP. The study was managed by the Primary Care Clinical Trials Unit and was funded by the NIHR School for Primary Care Research.

Of 565 eligible randomized participants (median age, 34 years), 288 received dexamethasone and 277 placebo. The researchers found that at 24 hours, participants receiving dexamethasone were not more likely than those receiving placebo to have complete symptom resolution. Results were similar among those who were not offered an antibiotic prescription and those who were offered a delayed antibiotic prescription. At 48 hours, more participants receiving dexamethasone than placebo (35 percent versus 27 percent) had complete symptom resolution, which was also observed in patients not offered delayed antibiotics. There were no significant differences in other outcomes such as days missed from work or school and adverse events.

The authors note that uncertainty remains about the role of oral corticosteroids for patients presenting in primary care with sore throat. “Corticosteroids may have clinical benefit in addition to antibiotics for severe sore throat, for example, to reduce hospital admissions of those patients who are unable to swallow fluids or medications. There have been no trials of corticosteroid use involving these patient groups.”

Read the paper:

Effect of oral dexamethasone without immediate antibiotics vs placebo on acute sore throat in adults a randomized clinical trial

Journal article

Hayward GN. et al, (2017), JAMA - Journal of the American Medical Association, 317, 1535 - 1543

 

Contact our communications team

Opinions expressed are those of the authors and not of Oxford University. Readers' comments will be moderated - see our guidelines for further information.

Departmental contributors:

Read the linked blog:

Can steroids soothe the thorny issue of acute sore throat?

Dr Gail Hayward discusses the outcome of the TOAST study, which aimed to better understand the role of steroids to treat sore throat.

Similar stories

Maternal RSV vaccine prevents hundreds of infant hospitalisations in first real-world national study

A major new study has shown that the risk of hospital admissions for young babies with serious respiratory infections reduced by more than 80% in Scotland following a new maternal vaccination programme against respiratory syncytial virus (RSV).

Primary Care Clinical Trials unit partners with Boots to recruit patients where they now seek care

A Boots pharmacy in Durham is recruiting patients to the DURATION trial, testing whether community pharmacies can support clinical research following the NHS Pharmacy First rollout. The pilot could reshape how primary care trials adapt to changing patient pathways.

Most penicillin 'allergies' not real, finds major trial coordinated by Department's Primary Care Clinical Trials Unit

A Department Clinical Trials Unit coordinated trial has found most penicillin 'allergies' are not real. Safely removing these incorrect labels can lead to better patient treatment and is a vital step in tackling the global threat of antimicrobial resistance.

Making medical research work where it matters most: Global team calls for revolution in GP and community health and care trials

An international team, led the Nuffield Department of Primary Care Health Sciences, is calling for a fundamental shift in how we conduct health research to better serve our real-world health and care needs.

New UK-Wide Centre to address growing respiratory health crisis

New UK-wide Centre for Applied Respiratory Research, Innovation and Impact (CARRii) launches at Oxford, aiming to reduce hospital admissions and health inequalities in respiratory care through innovative research and technology.

Antiviral molnupiravir offers only modest longer-term benefits for COVID-19, finds new paper from the PANORAMIC trial

Can the long-term consequences of COVID 19 be reduced through the use of novel antiviral medicines? New research from the PANORAMIC trial, run in NDPCHS Clinical Trial Unit and funded and delivered by the NIHR, has found that treating vaccinated, higher-risk adults with COVID-19 with the antiviral drug molnupiravir offers only modest benefits when it comes to reducing long term effects of the acute illness.